Apr 22, 2021 | Press Releases
As testing accelerates, company boosts manufacturing speed, output, and quality control with over 2 trillion cryopreserved NK cells ready for off-the-shelf use CULVER CITY, Calif., April 22, 2021– ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy...
Apr 8, 2021 | Press Releases
Preliminary Phase 1b findings in participants receiving the dual antigen hAd5 S + N vaccine generated Th1 dominant S and N specific T cells after a single prime subcutaneous injection The magnitude of this T cell response was equivalent to those seen for S & N T...
Apr 1, 2021 | Press Releases
CULVER CITY, Calif., April 1, 2021 – ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwell, M.D., MBA, as an independent member of the company’s board of...
Mar 30, 2021 | Press Releases
Second-generation human adenovirus (hAd5) targeting multiple tumor associated antigens (PSA, MUC-1, Brachyury) demonstrated safety, with no dose-limiting toxicities in patients with advanced prostate cancer Positive immune activation to PSA, MUC-1, and Brachyury...
Mar 22, 2021 | Press Releases
Checkpoint therapy alone is unlikely to lead to durable tumor control or a cure in patients with solid tumors that harbor DNA mutations that make them invisible to T cells This study supports ImmunityBio’s hypothesis of combining NK cells with T cell activation in...
Mar 15, 2021 | Press Releases
Safety assessments completed for first 12 participants and no serious adverse events (SAEs) reported; trials expected to be fully enrolled in Q2 First COVID-19 vaccine trials designed to deliver both S and N SARS-CoV-2 viral proteins via multiple routes—subcutaneous,...
